Evan Kearns's Insider Trades & SAST Disclosures

Evan Kearns's most recent trade in Cogent Biosciences Inc was a trade of 230,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 23, 2025.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Cogent Biosciences Inc
Evan Kearns Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2025 230,000 230,000 - - Stock Option (Right to Buy)
Cogent Biosciences Inc
Evan Kearns Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2024 255,000 255,000 - - Stock Option (Right to Buy)
Cogent Biosciences Inc
Evan Kearns Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2023 140,000 140,000 - - Stock Option (Right to Buy)
Cogent Biosciences Inc
Evan Kearns Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jan 2022 202,250 202,250 - - Stock Option (Right to Buy)
Agenus Inc
Evan Kearns VP and General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Dec 2020 150,000 150,000 - - Stock Option (Right to buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades